5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Acute O
Pancreatitis O
( O
postmarketing O
reports O
) O
: O
If O
pancreatitis O
is O
suspected O
, O
promptly O
discontinue O
ONGLYZA O
. O

( O
5.1 O
) O
* O
Hypoglycemia O
: O
In O
add-on O
to O
sulfonylurea O
, O
add-on O
to O
insulin O
, O
and O
add-on O
to O
metformin O
plus O
sulfonylurea O
trials O
, O
confirmed O
hypoglycemia O
was O
more O
common O
in O
patients O
treated O
with O
ONGLYZA O
compared O
to O
placebo O
. O

When O
used O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
insulin O
, O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
may O
be O
required O
to O
minimize O
the O
risk O
of O
hypoglycemia O
. O

( O
5.2 O
, O
6.1 O
) O
* O
Hypersensitivity-Related O
Events O
( O
e.g. O
, O
urticaria O
, O
facial O
edema O
) O
: O
More O
common O
in O
patients O
treated O
with O
ONGLYZA O
than O
in O
patients O
treated O
with O
placebo O
; O
and O
postmarketing O
reports O
of O
serious O
hypersensitivity O
reactions O
such O
as O
anaphylaxis O
, O
angioedema O
, O
and O
exfoliative O
skin O
conditions O
. O

Promptly O
discontinue O
ONGLYZA O
, O
assess O
for O
other O
potential O
causes O
, O
institute O
appropriate O
monitoring O
and O
treatment O
, O
and O
initiate O
alternative O
treatment O
for O
diabetes O
. O

( O
5.3 O
, O
6.1 O
, O
6.2 O
) O
* O
Arthralgia O
: O
Severe O
and O
disabling O
arthralgia O
has O
been O
reported O
in O
patients O
taking O
DPP4 O
inhibitors O
. O

Consider O
as O
a O
possible O
cause O
for O
severe O
joint O
pain O
and O
discontinue O
drug O
if O
appropriate O
. O

( O
5.4 O
) O
* O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular O
risk O
reduction O
with O
ONGLYZA O
or O
any O
other O
antidiabetic O
drug O
. O

( O
5.5 O
) O
5.1 O
Pancreatitis O
There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
in O
patients O
taking O
ONGLYZA O
. O

After O
initiation O
of O
ONGLYZA O
, O
patients O
should O
be O
observed O
carefully O
for O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
. O

If O
pancreatitis B-NonOSE_AE
is O
suspected O
, O
ONGLYZA O
should O
promptly O
be O
discontinued O
and O
appropriate O
management O
should O
be O
initiated O
. O

It O
is O
unknown O
whether O
patients O
with O
a O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
pancreatitis I-Not_AE_Candidate
are O
at O
increased O
risk O
for O
the O
development O
of O
pancreatitis B-NonOSE_AE
while O
using O
ONGLYZA O
. O

5.2 O
Hypoglycemia O
with O
Concomitant O
Use O
of O
Sulfonylurea O
or O
Insulin O
When O
ONGLYZA O
was O
used O
in O
combination O
with O
a O
sulfonylurea O
or O
with O
insulin O
, O
medications O
known O
to O
cause O
hypoglycemia B-NonOSE_AE
, O
the O
incidence O
of O
confirmed O
hypoglycemia B-NonOSE_AE
was O
increased O
over O
that O
of O
placebo O
used O
in O
combination O
with O
a O
sulfonylurea O
or O
with O
insulin O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Therefore O
, O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
may O
be O
required O
to O
minimize O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
when O
used O
in O
combination O
with O
ONGLYZA O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

5.3 O
Hypersensitivity O
Reactions O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
treated O
with O
ONGLYZA O
. O

These O
reactions O
include O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
. O

Onset O
of O
these O
reactions O
occurred O
within O
the O
first O
3 O
months O
after O
initiation O
of O
treatment O
with O
ONGLYZA O
, O
with O
some O
reports O
occurring O
after O
the O
first O
dose O
. O

If O
a O
serious O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
is O
suspected O
, O
discontinue O
ONGLYZA O
, O
assess O
for O
other O
potential O
causes O
for O
the O
event O
, O
and O
institute O
alternative O
treatment O
for O
diabetes B-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Use O
caution O
in O
a O
patient O
with O
a O
history O
of O
angioedema B-Not_AE_Candidate
to O
another O
dipeptidyl O
peptidase-4 O
( O
DPP4 O
) O
inhibitor O
because O
it O
is O
unknown O
whether O
such O
patients O
will O
be O
predisposed O
to O
angioedema B-NonOSE_AE
with O
ONGLYZA O
. O

5.4 O
Severe O
and O
Disabling O
Arthralgia O
There O
have O
been O
postmarketing O
reports O
of O
severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
in O
patients O
taking O
DPP4 O
inhibitors O
. O

The O
time O
to O
onset O
of O
symptoms O
following O
initiation O
of O
drug O
therapy O
varied O
from O
one O
day O
to O
years O
. O

Patients O
experienced O
relief O
of O
symptoms O
upon O
discontinuation O
of O
the O
medication O
. O

A O
subset O
of O
patients O
experienced O
a O
recurrence O
of O
symptoms O
when O
restarting O
the O
same O
drug O
or O
a O
different O
DPP4 O
inhibitor O
. O

Consider O
DPP4 O
inhibitors O
as O
a O
possible O
cause O
for O
severe O
joint B-NonOSE_AE
pain I-NonOSE_AE
and O
discontinue O
drug O
if O
appropriate O
. O

5.5 O
Macrovascular O
Outcomes O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular B-NonOSE_AE
risk I-NonOSE_AE
reduction O
with O
ONGLYZA O
or O
any O
other O
antidiabetic O
drug O
. O

